Finally, the consistent downregulation of NFE2 and PF4 transcription within hours post BMS-986158 treatment in both preclinical and clinical studies (Figures 3, 4), along with the observed dose-dependent decrease in platelet counts (Figure 2), supports their potential as prodromal biomarkers for predicting thrombocytopenia induced by BET inhibition. The gene discussed is NFE2; the disease is Thrombocytopenia.